There is an unmet need for point-of-care therapies to prevent scarring and promote corneal clarity after injury, which is essential for the patients to maintain their vision and life quality. Verteporfin, an inhibitor of Yes-associated protein (YAP) related to scar formation, has been shown to prevent fibrosis in several organs. Visudyne (VP) is an FDA-approved liposomal formulation of verteporfin to treat abnormal blood vessels in the eye. Here, we showed that Visudyne reduces myofibroblast formation in corneal stromal fibroblasts. To prolong the residence of verteporfin on the ocular surface, the cohesive viscoelastic ProVisc® hyaluronic acid (HA) gel was used to prolong the release of verteporfin. This formulation is readily translatable because both Visudyne and the ProVisc® HA gel are FDA-approved agents. The ProVisc® HA gel increased the residence of subconjunctivally injected verteporfin 12-fold at 24 h after injection than pure Visudyne. A single subconjunctival administration of VP hybridized within ProVisc® HA gel (VP/HA hydrogel) significantly reduced YAP activation, corneal fibrosis, neovascularization, and inflammation, leading to reduced opacity without compromising epithelial wound healing in mechanically injured rat corneas. This work demonstrated that Visudyne hybridized with a viscoelastic HA gel can be readily repurposed to promote scar-less healing in the cornea.